Registry update — unassessed
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: A Phase 2, Single-Center, 20-week, Open-Label, Randomized Controlled Trial.
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 22, 2024 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract does not report what the study actually found, making it impossible to assess whether senolytics achieved the stated objectives or produced clinically meaningful changes in bone health
- Open-label design means both participants and staff knew treatment assignment, allowing bias in outcome assessment
- Clinical bone health improvements (fracture risk, bone density, strength) were not stated as outcomes measured
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 5 months
- Population
- Elderly women
- Primary outcome
- Reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers
- Effect size
- —
- Significance
- Not reported
- Journal
- Not clearly reported; author named as Sundeep Khosla, M.D.
- Published
- Jul 22, 2024
Sources
Primary source
- Sundeep Khosla, M.D. ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Title: Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: A Phase 2, Single-Center, 20-week, Open-Label, Randomized Controlled Trial
To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers in elderly women
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.